|
15 Jan 2021 |
Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
|
|
15 Jan 2021 |
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
|
|
15 Jan 2021 |
Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
|
|
15 Jan 2021 |
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
|
|
15 Jan 2021 |
Ubiquigent and the University of York Awarded a Grant to Explore the Potential of Deubiquitylase (DUB) Enzyme Inhibitors to Address Neglected Tropical Diseases
|
|
15 Jan 2021 |
Syntekabio Signs Joint Development Agreement with Hanmi Science
|
|
14 Jan 2021 |
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
|
|
14 Jan 2021 |
Vor Announces FDA Clearance of IND Application for VOR33
|
|
14 Jan 2021 |
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
|
|
13 Jan 2021 |
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
|
|
13 Jan 2021 |
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
|
|
13 Jan 2021 |
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
|
|
13 Jan 2021 |
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
|
|
13 Jan 2021 |
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
|
|
13 Jan 2021 |
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
|
|
13 Jan 2021 |
Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas
|
|
13 Jan 2021 |
LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
|
|
13 Jan 2021 |
Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
|
|
13 Jan 2021 |
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
|
|
13 Jan 2021 |
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
|
